store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MKK7-COV-9 是一种具有选择性和有效性的 MKK7 共价抑制剂,对 MKK7 引导的蛋白-蛋白相互作用有抑制作用。MKK7-COV-9 中断原代 B 细胞应对 LPS 的激活。MKK7-COV-9 在高浓度下显示出较低的细胞毒性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 1,470 | 现货 | ||
5 mg | ¥ 2,480 | 现货 | ||
10 mg | ¥ 3,980 | 现货 | ||
25 mg | ¥ 7,850 | 现货 | ||
50 mg | ¥ 10,600 | 现货 | ||
100 mg | ¥ 14,300 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,730 | 现货 |
产品描述 | MKK7-COV-9 is a selective and potent covalent inhibitor of MKK7 with inhibitory effects on MKK7-induced protein-protein interactions.MKK7-COV-9 interrupts the activation of primary B-cells in response to LPS.MKK7-COV-9 shows low cytotoxicity at high concentrations. |
靶点活性 | 3T3 cells:4.06 μM (EC50) |
体外活性 |
Due to poor permeability, the piperidine analogs MKK7-COV-10 and MKK7-COV-11, as well as the carboxylic acid MKK7-COV-8, prove to be inactive in ICW in 3T3 cells. In contrast, the amide counterpart, MKK7-COV-9, retains activity (EC50=4.06 μM) and provides a new vector for further derivatization[1]. MKK7-COV-9 (10 μM; 48 hours) shows a limited cytotoxic effect only at the highest tested concentration. Only one cell line, HCT116, displayed a half-maximal lethal dose (LD50) < 10 μM for these two compounds[1].With a 2-hour pre-incubation at 10 μM, MKK7-COV-9 is able to inhibit 60% of the CD86+ response to LPS stimulation in primary mouse B cells, except the negative control MKK7-NEG-1[1].JNK is known to mediate the activation of B cells in response to lipopolysaccharide through the TLR4 signaling pathway.MKK7-COV-9 (0-10 μM; 2 hr pre-incubation) is able to mediate the activation of B cells in response to LPS through the TLR4 signaling pathway. It shows a dose-response curve for the inhibition of LPS-induced activation and exhibits an EC50 value of 4.98 μM (EC50=4.98 μM for MKK7-COV-12; EC50>10 μM for MKK7-COV-7; EC50=2.23 μM for JNK-IN-8)[1]. |
分子量 | 320.35 |
分子式 | C18H16N4O2 |
CAS No. | 2283355-59-7 |
store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10 mg/mL (31.22 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.1216 mL | 15.6079 mL | 31.2159 mL | 78.0396 mL |
5 mM | 0.6243 mL | 3.1216 mL | 6.2432 mL | 15.6079 mL | |
10 mM | 0.3122 mL | 1.5608 mL | 3.1216 mL | 7.804 mL | |
20 mM | 0.1561 mL | 0.7804 mL | 1.5608 mL | 3.902 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
MKK7-COV-9 2283355-59-7 Others Inhibitor inhibitor inhibit